Related references
Note: Only part of the references are listed.Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data
A. Cranney et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: A 12-month, open-label, prospective evaluation
E. Michael Lewiecki et al.
CLINICAL THERAPEUTICS (2008)
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)
Peyman Hadji et al.
JOINT BONE SPINE (2008)
Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance
S. Boonen et al.
JOURNAL OF INTERNAL MEDICINE (2008)
Compliance and persistence with osteoporosis therapies
Stuart L. Silverman et al.
Current Rheumatology Reports (2008)
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
Steven T. Harris et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025
Russel Burge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Prediction and discrimination of osteoporotic hip fracture in postmenopausal women
Claire Durosier et al.
JOURNAL OF CLINICAL DENSITOMETRY (2006)
Clinical utility of spine bone density in elderly women
Diane L. Schneider et al.
JOURNAL OF CLINICAL DENSITOMETRY (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Intravenous ibandronate injections in postmenopausal women with osteoporosis - One-year results from the dosing intravenous administration study
Pierre D. Delmas et al.
ARTHRITIS AND RHEUMATISM (2006)
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)
R Emkey et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Predictive value of BMD for hip and other fractures
O Johnell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Epidemiology of osteoporotic fractures
Olof Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2005)
The burden of hospitalised fractures in Sweden
O Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Pharmacokinetics/pharmacodynamics of bisphosphonates - Use for optimisation of intermittent therapy for osteoporosis
SCLM Cremers et al.
CLINICAL PHARMACOKINETICS (2005)
Ibandronate: A clinical pharmacological and pharmacokinetic update
J Barrett et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Mortality after osteoporotic fractures
O Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2004)
The components of excess mortality after hip fracture
JA Kanis et al.
BONE (2003)
Epidemiology and outcomes of osteoporotic fractures
SR Cummings et al.
LANCET (2002)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Risk of mortality following clinical fractures
JA Cauley et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
